Entwicklung eines Biomarkers und biochemischen Tests zur Diagnose von Sarkopenie (altersbedingter Muskelschwund)

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

8908.1;5 PFLS-LS

Projekttitel

Entwicklung eines Biomarkers und biochemischen Tests zur Diagnose von Sarkopenie (altersbedingter Muskelschwund)

Projekttitel Englisch

Entwicklung eines Biomarkers und biochemischen Tests zur Diagnose von Sarkopenie (altersbedingter Muskelschwund)

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Entwicklung eines Biomarkers und biochemischen Tests zur Diagnose von Sarkopenie (altersbedingter Muskelschwund)
Abstract (Englisch)	Establishment of a biomarker for in vivo activity of Neurotrypsin and development of an in-vitro test to diagnose sarcopeniaThe goal of the proposed project is develop a commercial test to monitor the activity of the synapse-modulating protease Neurotrypsin, by measuring the product of Neurotrypsin¿s proteolytic activity. The assay for the Neurotrypsin-dependent biomarker in the cerebrospinal fluid and the blood will provide an important tool to monitor Neurotrypsin activity during preclinical and clinical stages of our drug development projects with small molecule inhibitors of Neurotrypsin. The assay for the biomarker will also provide the basis for the development of a diagnostic test for Neurotrypsin activity in the context of neuro-psychiatric disturbances, as well as Neurotrypsin-related disturbances outside of the nervous system.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Entwicklung eines Biomarkers und biochemischen Tests zur Diagnose von Sarkopenie (altersbedingter Muskelschwund)

Abstract
(Englisch)

Establishment of a biomarker for in vivo activity of Neurotrypsin and development of an in-vitro test to diagnose sarcopeniaThe goal of the proposed project is develop a commercial test to monitor the activity of the synapse-modulating protease Neurotrypsin, by measuring the product of Neurotrypsin¿s proteolytic activity. The assay for the Neurotrypsin-dependent biomarker in the cerebrospinal fluid and the blood will provide an important tool to monitor Neurotrypsin activity during preclinical and clinical stages of our drug development projects with small molecule inhibitors of Neurotrypsin. The assay for the biomarker will also provide the basis for the development of a diagnostic test for Neurotrypsin activity in the context of neuro-psychiatric disturbances, as well as Neurotrypsin-related disturbances outside of the nervous system.